These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17488666)

  • 1. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
    Kastritis E; Anagnostopoulos A; Roussou M; Gika D; Matsouka C; Barmparousi D; Grapsa I; Psimenou E; Bamias A; Dimopoulos MA
    Haematologica; 2007 Apr; 92(4):546-9. PubMed ID: 17488666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reply. Kastritis E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimes and the impact of novel agents. Haematologica 2007; 92:546-9.
    Bergner R; Hoffmann M; Uppenkamp M
    Haematologica; 2008 Jan; 93(1):e18-9. PubMed ID: 18166771
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
    Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
    Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
    Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
    Chen RA; Tu Y; Cao Y; Liu L; Liang Y
    J Int Med Res; 2011; 39(5):1975-84. PubMed ID: 22118002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy for multiple myeloma].
    Ishida T
    Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New insights in the treatment of myeloma with renal failure].
    Moumas E; Hanf W; Desport E; Abraham J; Delbès S; Debiais C; Lacotte-Thierry L; Touchard G; Jaccard A; Fermand JP; Bridoux F
    Nephrol Ther; 2011 Nov; 7(6):457-66. PubMed ID: 21515102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
    Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
    Roussou M; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Grapsa I; Psimenou E; Gika D; Terpos E; Dimopoulos MA
    Leuk Res; 2010 Oct; 34(10):1395-7. PubMed ID: 20510452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
    Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Islam A; Ambrus JL
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19073984
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
    Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
    Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.